logo
logo

Petdx Raises $62 Million In Series B Financing To Scale Adoption Of Its Canine Multi-Cancer Early Detection Blood Test, Oncok9

Dec 09, 2021over 3 years ago

Amount Raised

$62 Million

Round Type

series b

San DiegoBiotechnologyFinancial ServicesHealth CareCommunity And Lifestyle

Description

PetDx® today announced the completion of its Series B financing with over $62 million in new capital raised, which is one of the biggest Series B rounds for a pet startup; bringing the company's total funding to date to $72 million. The financing was led by Longview Asset Management with participation by Declaration Partners, Torch Capital, Aperture Venture Partners, Valor Equity Partners, Friedman Bioventure, K4 Family Investments, and Labcorp (NYSE:LH). The company's $10M Series A financing in August 2020 was led by Friedman Bioventure with participation from Petco (Nasdaq:WOOF) and an undisclosed leading pet healthcare company.

Company Information

Company

Pet Dx

Location

San Diego, California, United States

About

PetDx® – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients. To learn more, visit www.petdx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech